[1] |
SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
|
[2] |
LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 6. DOI: 10.1038/s41572-020-00240-3.
|
[3] |
ZHENG RS, ZHANG SW, ZENG HM, et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Cent, 2022, 2( 1): 1- 9.
|
[4] |
de MARTEL C, GEORGES D, BRAY F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8( 2): e180-e190. DOI: 10.1016/S2214-109X(19)30488-7.
|
[5] |
YANG SL, LUO YY, CHEN M, et al. A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy[J]. HPB(Oxford), 2017, 19( 10): 835- 842. DOI: 10.1016/j.hpb.2017.06.002.
|
[6] |
TSILIMIGRAS DI, BAGANTE F, SAHARA K, et al. Prognosis after resection of Barcelona Clinic Liver Cancer(BCLC) stage 0, A, and B hepatocellular carcinoma: A comprehensive assessment of the current BCLC classification[J]. Ann Surg Oncol, 2019, 26( 11): 3693- 3700. DOI: 10.1245/s10434-019-07580-9.
|
[7] |
General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
|
[8] |
GUO LW, ZHANG SK, LIU SZ, et al. Compliance rate and impact factor analysis of liver cancer screening in urban areas of Henan Province[J]. Chin J Oncol, 2021, 43( 2): 233- 237. DOI: 10.3760/cma.j.cn112152-20200331-00286.
郭兰伟, 张韶凯, 刘曙正, 等. 河南省城市地区肝癌筛查依从性及其影响因素分析[J]. 中华肿瘤杂志, 2021, 43( 2): 233- 237. DOI: 10.3760/cma.j.cn112152-20200331-00286.
|
[9] |
MA YL, QIAN LT, WEI DH, et al. The compliance of liver cancer screening and related influencing factors in Hefei City of Anhui Province from 2014 to 2017[J]. China Cancer, 2021, 30( 12): 895- 900. DOI: 10.11735/j.issn.1004-0242.2021.12.A003.
马艳玲, 钱立庭, 魏东华, 等. 2014-2017年安徽省合肥市城市肝癌高危人群筛查依从性及其相关影响因素分析[J]. 中国肿瘤, 2021, 30( 12): 895- 900. DOI: 10.11735/j.issn.1004-0242.2021.12.A003.
|
[10] |
Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
|
[11] |
ZHENG XY. Guiding principles for clinical research of new traditional Chinese medicine(Trial)[M]. Beijing: China Medical Science Press, 2002.
郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002.
|
[12] |
SHIM JJ, KIM GA, OH CH, et al. Reduced liver cancer mortality with regular clinic follow-up among patients with chronic hepatitis B: A nationwide cohort study[J]. Cancer Med, 2020, 9( 20): 7781- 7791. DOI: 10.1002/cam4.3421.
|
[13] |
LIU C, DAI JY, ZHAO J. Changes in adherence to hepatocellular carcinoma surveillance among high-risk population in a hospital in Yunnan and the related influencing factors[J]. Chin Prev Med, 2023, 24( 2): 122- 128. DOI: 10.16506/j.1009-6639.2023.02.006.
刘畅, 戴静毅, 赵军. 2018—2019年云南省某医院肝癌高危人群肝癌监测依从性变化及影响因素分析[J]. 中国预防医学杂志, 2023, 24( 2): 122- 128. DOI: 10.16506/j.1009-6639.2023.02.006.
|
[14] |
ZHANG BH, YANG BH, TANG ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130( 7): 417- 422. DOI: 10.1007/s00432-004-0552-0.
|
[15] |
MARRERO JA, KULIK LM, SIRLIN CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68( 2): 723- 750. DOI: 10.1002/hep.29913.
|
[16] |
HOU JL, ZHAO W, LEE C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol, 2020, 18( 2): 457- 467. DOI: 10.1016/j.cgh.2019.07.010.
|
[17] |
CHEEWAKRIANGKRAI C, KIETPEERAKOOL C, CHAROENKWAN K, et al. Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer[J]. Cochrane Database Syst Rev, 2020, 3( 3): CD013253. DOI: 10.1002/14651858.CD013253.pub2.
|
[18] |
MUSA J, ACHENBACH CJ, O'DWYER LC, et al. Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis[J]. PLoS One, 2017, 12( 9): e0183924. DOI: 10.1371/journal.pone.0183924.
|
[19] |
ZHU CH, WU YK, LI XY, et al. The compliance and its affecting factors with treatment guideline recommendations of chronic HBV infection: A long-term follow-up cohort study[J]. Guangdong Med J, 2016, 37( 23): 3578- 3582. DOI: 10.3969/j.issn.1001-9448.2016.23.030.
朱昌浩, 吴元凯, 李向永, 等. 慢性HBV感染者长期随访队列患者依从性现状及其影响因素[J]. 广东医学, 2016, 37( 23): 3578- 3582. DOI: 10.3969/j.issn.1001-9448.2016.23.030.
|